RecruitingPhase 2NCT04551482

Oxytocin for Weight Loss in Adolescents

Oxytocin as a Neuroendocrine Therapy for Obesity in Youth


Sponsor

Massachusetts General Hospital

Enrollment

55 participants

Start Date

Jul 28, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 10-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments.


Eligibility

Min Age: 10 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Oxytocin nasal spray and a drug called Placebo for people with obesity, adolescent and oxytocin. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOxytocin nasal spray

24 IU nasal spray, 4 times per day for 12 weeks

DRUGPlacebo

24 IU nasal spray, 4 times per day for 12 weeks


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04551482


Related Trials